AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
 and a Lead Plaintiff Deadline of April 10, 2017 - EconoTimes)
NEW YORK, March 28, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Global Brokerage, Inc. (NASDAQ:GLBR), formerly known as FXCM, Inc. (NASDAQ:FXCM) securities between March 15, 2012 and February 6, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/fxcm-inc. There is no cost or obligation to you.
The complaint alleges that during the class period the Company made false and/or misleading statements and/or failed to disclose that: (1) from September 4, 2009 through at least 2014, FXCM’s U.S. subsidiary engaged in false and misleading solicitations of its retail foreign exchange customers by concealing its relationship with its most important market maker and by misrepresenting that its “No Dealing Desk” platform had no conflicts of interest with its customers; (2) FXCM’s U.S. subsidiary made false statements to the National Futures Association about its relationship with the market maker; and (3) as a result, Defendants’ statements about FXCM’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in FXCM you have until April 10, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/fxcm-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
